TY - JOUR
T1 - Genomic alterations in thyroid cancer
T2 - biological and clinical insights
AU - Landa, Iñigo
AU - Cabanillas, Maria E.
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2024/2
Y1 - 2024/2
N2 - Tumours can arise from thyroid follicular cells if they acquire driver mutations that constitutively activate the MAPK signalling pathway. In addition, a limited set of additional mutations in key genes drive tumour progression towards more aggressive and less differentiated disease. Unprecedented insights into thyroid tumour biology have come from the breadth of thyroid tumour sequencing data from patients and the wide range of mutation-specific mechanisms identified in experimental models, in combination with the genomic simplicity of thyroid cancers. This knowledge is gradually being translated into refined strategies to stratify, manage and treat patients with thyroid cancer. This Review summarizes the biological underpinnings of the genetic alterations involved in thyroid cancer initiation and progression. We also provide a rationale for and discuss specific examples of how to implement genomic information to inform both recommended and investigational approaches to improve thyroid cancer prognosis, redifferentiation strategies and targeted therapies.
AB - Tumours can arise from thyroid follicular cells if they acquire driver mutations that constitutively activate the MAPK signalling pathway. In addition, a limited set of additional mutations in key genes drive tumour progression towards more aggressive and less differentiated disease. Unprecedented insights into thyroid tumour biology have come from the breadth of thyroid tumour sequencing data from patients and the wide range of mutation-specific mechanisms identified in experimental models, in combination with the genomic simplicity of thyroid cancers. This knowledge is gradually being translated into refined strategies to stratify, manage and treat patients with thyroid cancer. This Review summarizes the biological underpinnings of the genetic alterations involved in thyroid cancer initiation and progression. We also provide a rationale for and discuss specific examples of how to implement genomic information to inform both recommended and investigational approaches to improve thyroid cancer prognosis, redifferentiation strategies and targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=85178463373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178463373&partnerID=8YFLogxK
U2 - 10.1038/s41574-023-00920-6
DO - 10.1038/s41574-023-00920-6
M3 - Review article
C2 - 38049644
AN - SCOPUS:85178463373
SN - 1759-5029
VL - 20
SP - 93
EP - 110
JO - Nature Reviews Endocrinology
JF - Nature Reviews Endocrinology
IS - 2
ER -